Clinical Inquiries

Do electronic reminder systems help patients with T2DM to lose weight?

Author and Disclosure Information

EVIDENCE-BASED ANSWER:

PROBABLY NOTbut they may augment self-management. Four-component telehealth systems—including electronic reminders, measuring devices, patient-driven data upload, and remote data analysis—likely don’t result in significant weight reductions in adults with type 2 diabetes (T2DM). However, their use may be associated with a decrease in hemoglobin A1C of about 0.4% (strength of recommendation [SOR]: B, meta-analysis of randomized controlled trials [RCTs] and conflicting smaller subsequent RCTs).

Telehealth is considered a reasonable option for augmenting diabetes self-­management in patients who are facile with the technology (SOR: C, expert ­opinion).


 

References

EVIDENCE SUMMARY

A meta-analysis of 6 RCTs studied the effect of smartphone self-care applications on A1C, weight, blood pressure, and lipids in adult patients with T2DM. All the interventions comprised 4 components: electronic self-management prompts and reminders, personal measuring devices, patient-driven data upload, and remote analysis of the data with feedback. The review excluded studies that used phone calls or lasted fewer than 3 months.

Some improvement in A1C found, but no effect on weight

Telehealth interventions improved A1C more than usual care (6 trials, 884 patients; mean difference = –0.40%; 95% CI, –0.69% to –0.11%).1 A subset of 4 studies with 560 patients evaluated changes in weight. Patients had a mean age of 61 years and average weight of 84 kg (in 3 of 4 studies reporting baseline weight). Aggregate weight loss was insignificant after 3 to 12 months (mean difference = –0.84 kg; 95% CI, –2.04 kg to 0.36 kg, P = .17). Investigators reported no harms. Limitations of the analysis included high heterogeneity in the main outcome of A1C (I2 = 70%) but low heterogeneity within the 4 studies assessing weight (I2 = 30%).

Other, small studies found no change in A1C

Two subsequent small RCTs came to different conclusions than the meta-analysis. One compared the impact of individualized physical activity–based text messages in response to pedometer readings with pedometer use alone.2 It included 126 adult patients (mean age, 50.5 years) with T2DM who had an A1C > 7% and access to an Internet-connected computer. Researchers excluded patients who were unable to perform moderate physical activity or who had cognitive deficits.

At enrollment, researchers supplied all patients with a pedometer and an appointment with a counselor to set goals for physical activity. They sent 2 text messages daily to the intervention group (and none to the control group) based on uploaded pedometer data. One message detailed physical activity progress and the second encouraged increased physical activity. The primary outcome was mean step counts per month; secondary outcomes included A1C and weight measured at 6 months.

The groups showed no significant difference in A1C (mean difference = 0.07%; 95% CI, –0.47% to 0.34%, P = .75) or weight loss (mean difference = 3.1 lb; 95% CI, –24.5 lb to 18.3 lb, P = .77). Many patients (43%) reported difficulty uploading step counts, receiving texts, and responding to texts. The dropout rate was 24%.

A second RCT with 150 patients, using a less elaborate protocol, assessed the effectiveness of tailored text-message reminders compared with nontailored text messages to improve A1C and body mass index (BMI).3 Patients were adult Iranians (mean age, 52.5 years) with T2DM who owned a cell phone and could receive and read text messages.

Patients filled out a diabetic self-care assessment to identify barriers to improving care and were randomized into 3 groups. The first group received tailored text messages (75% addressing the patient’s top 2 barriers to self-care and 25% general messages). The second group received nontailored text messages of encouragement. The control group received no text messages.

Continue to: After 3 months...

Pages

Evidence-based answers from the Family Physicians Inquiries Network

Recommended Reading

Recall widens for diabetes drug metformin
MDedge Family Medicine
COVID-19 antibody response not reduced with diabetes
MDedge Family Medicine
Experts tout immediate quadruple therapy for HFrEF patients
MDedge Family Medicine
Novel drug slows progression of diabetic kidney disease
MDedge Family Medicine
Online tool offers diabetes device information free of industry funding
MDedge Family Medicine
HIV drugs prevent type 2 diabetes, may be path to new therapy
MDedge Family Medicine
Diabetes screening program in optometry offices to expand
MDedge Family Medicine
First-of-its kind guideline on lipid monitoring in endocrine diseases
MDedge Family Medicine
Medication adherence challenges and helpers
MDedge Family Medicine
PCI success vs. meds only in diabetes may depend on LDL-C control
MDedge Family Medicine